Changeflow GovPing Healthcare & Life Sciences Oleic Acid Derivatives as Treatments for Friedr...
Routine Notice Added Final

Oleic Acid Derivatives as Treatments for Friedreich Ataxia and Ferroptosis Inhibitors

Favicon for changeflow.com USPTO Patent Applications - Therapeutics (A61P)
Published
Detected
Email

Summary

The USPTO published patent application US20260109661A1 on April 23, 2026, filed by The Trustees of the University of Pennsylvania. The application covers oleic acid derivatives of Formula I or Formula II, compositions containing them, and methods of use for treating neurodegenerative disorders including Friedreich ataxia, as well as compounds acting as ferroptosis inhibitors. Seven inventors are named: Amos Smith, Robert B. Wilson, Donna M Huryn, Maria Grazia Cotticelli, Shujuan Xia, Taehee Lee, and Roberto Forestieri.

“The invention relates to compounds of Formula I or Formula II: to compositions comprising such compounds, and to methods of use thereof for treating neurodegenerative disorders, such as Friedreich ataxia.”

USPTO , verbatim from source
Published by USPTO on changeflow.com . Detected, standardized, and enriched by GovPing. Review our methodology and editorial standards .

About this source

GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 223 changes logged to date.

What changed

The USPTO published patent application US20260109661A1 on April 23, 2026, covering oleic acid derivatives of Formula I or Formula II for treating neurodegenerative disorders, specifically Friedreich ataxia, and for inhibiting ferroptosis. The application names The Trustees of the University of Pennsylvania as assignee and lists seven inventors including Amos Smith, Robert B. Wilson, Donna M Huryn, Maria Grazia Cotticelli, Shujuan Xia, Taehee Lee, and Roberto Forestieri.

This publication does not constitute a granted patent or create any regulatory obligations. Researchers and biotech companies in the neurodegenerative disease space may review the filing to understand the University of Pennsylvania's IP position in the Friedreich ataxia treatment landscape.

Archived snapshot

Apr 24, 2026

GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.

← USPTO Patent Applications

OLEIC ACID DERIVATIVES AS TREATMENTS FOR FRIEDREICH ATAXIA AND INHIBITORS OF FERROPTOSIS

Application US20260109661A1 Kind: A1 Apr 23, 2026

Assignee

THE TRUSTEES OF THE UNIVERSITY OF PENNSYLVANIA

Inventors

Amos SMITH, Robert B. WILSON, Donna M Huryn, Maria Grazia Cotticelli, Shujuan XIA, Taehee LEE, Roberto FORESTIERI

Abstract

The invention relates to compounds of Formula I or Formula II: to compositions comprising such compounds, and to methods of use thereof for treating neurodegenerative disorders, such as Friedreich ataxia.

CPC Classifications

C07C 33/423 A61P 25/14 C07C 49/227

Filing Date

2025-06-27

Application No.

19253400

View original document →

Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)

Daily digest delivered to your inbox.

Free. Unsubscribe anytime.

About this page

What is GovPing?

Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission

What's from the agency?

Source document text, dates, docket IDs, and authority are extracted directly from USPTO.

What's AI-generated?

The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.

Last updated

Classification

Agency
USPTO
Published
April 23rd, 2026
Instrument
Notice
Branch
Executive
Legal weight
Non-binding
Stage
Final
Change scope
Minor

Who this affects

Applies to
Pharmaceutical companies Healthcare providers Researchers
Industry sector
3254 Pharmaceutical Manufacturing
Activity scope
Patent application filing Drug development research Biotechnology IP
Geographic scope
United States US

Taxonomy

Primary area
Intellectual Property
Operational domain
Legal
Topics
Public Health Pharmaceuticals

Get alerts for this source

We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.

Free. Unsubscribe anytime.

You're subscribed!